CRISPR-Based Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Enzymes, Kits and Reagents, Software and Libraries), By Technology (Cas9, Cas12, Others), By Application (Infectious Disease Diagnostics, Genetic Disorder Diagnostics, Cancer Diagnostics, Others), By End User (Hospitals and Clinics Diagnostic, Laboratories, Pharmaceutical and Biotechnology Companies, Others), By Region and Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 3.68 Billion
CAGR (2026-2031)	17.37%
Fastest Growing Segment	Cancer Diagnostics
Largest Market	North America
Market Size (2031)	USD 9.62 Billion

Market Overview

The Global CRISPR-Based Diagnostics Market is projected to grow from USD 3.68 Billion in 2025 to USD 9.62 Billion by 2031 at a 17.37% CAGR. CRISPR-based diagnostics utilize Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology for the highly sensitive and specific detection of nucleic acids, thereby facilitating rapid and accurate diagnosis of various diseases. Key drivers supporting this market's growth include the increasing global prevalence of infectious diseases, the rising demand for efficient point-of-care testing solutions, and continuous advancements in CRISPR gene-editing technologies that enhance diagnostic speed and accuracy.

A significant challenge that could impede market expansion is the complex regulatory landscape, coupled with the rigorous need for extensive validation studies to successfully integrate these novel diagnostic platforms into existing clinical workflows. While substantial market growth projections exist within the broader diagnostics industry, statistical numerical data specifically pertaining to the Global CRISPR-Based Diagnostics Market from an industrial association within the last year, as stipulated, could not be identified through available public information.

Key Market Drivers

Growing global disease burden
The increasing global burden of infectious and genetic diseases represents a primary driving force for the Global CRISPR-Based Diagnostics Market, as the necessity for timely and accurate disease identification continues to escalate. These diagnostic tools offer the specificity and sensitivity required to combat widespread health challenges effectively. For instance, according to the World Health Organization's Global Tuberculosis Report 2025, released in November 2025, tuberculosis claimed over 1.2 million lives and affected an estimated 10.7 million people in 2024. The substantial prevalence of such diseases underscores the critical need for advanced diagnostic platforms capable of rapid and reliable detection, thereby reducing disease transmission and improving patient outcomes.

Technological advancements in CRISPR-based diagnostics
Technological advancements in CRISPR systems further propel market expansion by enhancing the capabilities and accessibility of diagnostic solutions. Continuous innovation leads to more refined CRISPR-Cas enzyme systems, improved detection methods, and integration into user-friendly platforms suitable for various clinical settings, including point-of-care testing. This advancement is notably reflected in investment activities; according to a November 2025 news article, CrisprBits, a Bengaluru biotech startup, raised $3 million in a pre-Series A round to scale its CRISPR-based diagnostics and gene-editing platforms. Such funding supports the translation of research into commercial products, directly contributing to the broader market. Overall, according to Towards Healthcare, in April 2026, the global CRISPR technology market size reached USD 6.67 billion in 2025, reflecting sustained growth and investor confidence in this transformative diagnostic technology.

Download Free Sample Report

Key Market Challenges

The complex regulatory landscape, coupled with the rigorous need for extensive validation studies, significantly impedes the expansion of the Global CRISPR-Based Diagnostics Market. Developing and gaining approval for novel diagnostic platforms, especially those leveraging advanced genetic technologies such as CRISPR, is an inherently lengthy and resource-intensive process. This requires navigating varied and often evolving regulatory frameworks across numerous international jurisdictions, which creates substantial uncertainty and increases the cost burden for developers.

The necessity for comprehensive clinical validation, involving multi-site trials and demonstrating equivalence or superiority to existing diagnostic methods, further prolongs market entry. This extended development and approval timeline delays the availability of these innovative tools to healthcare providers and patients. According to the Advanced Medical Technology Association (AdvaMed), in 2025, the average time to market for high-risk in vitro diagnostic devices, which often includes novel technologies, can exceed five years in certain regions due to stringent regulatory review and extensive validation requirements. These delays and high associated costs, often reaching tens of millions of dollars per product for advanced diagnostics, can deter investment and slow the commercialization of new CRISPR-based diagnostic solutions.

Key Market Trends

The development of multiplexed diagnostic assays represents a pivotal trend, enabling the simultaneous detection of multiple biomarkers or pathogens in a single test. This capability significantly enhances diagnostic efficiency and provides a more comprehensive understanding of complex disease states, moving beyond single-target detection limitations. Such advancements are crucial for applications where co-infections are common or when differentiating between various disease etiologies is necessary for effective treatment. For instance, according to MDPI, in May 2025, researchers described a multiplexed assay in a 3D-printed 96-well plate to target three circulating blood biomarker microRNAs for Alzheimer's disease, demonstrating high sensitivity in simultaneously identifying multiple disease indicators. This approach streamlines diagnostic workflows, particularly for conditions requiring a panel of markers for accurate assessment.

Another significant trend is the diversification of readout mechanisms, improving the accessibility and user-friendliness of CRISPR-based diagnostics across various settings. Innovations focus on integrating CRISPR technology with portable, low-cost, and instrument-free detection systems, making molecular diagnostics available outside traditional laboratories. This includes developing visual, colorimetric, or smartphone-integrated readouts, thereby facilitating point-of-care testing and diagnostic decentralization. According to an article in Nature Biotechnology, in May 2026, a new DNA-guided CRISPR system was reported to simplify clinical diagnostics, demonstrating 100% accuracy in detecting hepatitis C, underscoring the potential for more affordable and widely accessible diagnostic solutions. This shift towards diverse and accessible readout methods is vital for expanding the global reach of CRISPR diagnostics.

Segmental Insights

Cancer Diagnostics is emerging as the fastest-growing segment within the Global CRISPR-Based Diagnostics Market. This rapid expansion is primarily driven by the increasing global incidence of various cancer types, which fuels a significant demand for advanced diagnostic tools capable of early and accurate detection. CRISPR-based technologies are being widely adopted into next-generation diagnostic platforms due to their inherent ability to provide rapid, highly sensitive, and specific real-time results. Furthermore, ongoing advancements in guide RNA libraries and CRISPR screening techniques are instrumental in accelerating the identification of novel biomarkers associated with cancer, thereby enhancing diagnostic precision and facilitating the development of targeted therapeutic strategies.

Regional Insights

North America dominates the Global CRISPR-Based Diagnostics Market due to its robust research and development infrastructure and the significant presence of leading biotechnology companies. The region benefits from substantial investments in advanced diagnostics and a strong focus on personalized medicine. Furthermore, a supportive regulatory environment, exemplified by initiatives from bodies such as the U.S. Food and Drug Administration (FDA) to streamline approval processes for innovative diagnostic tools, fosters early adoption and commercialization. This, combined with a high prevalence of chronic and infectious diseases, drives the increasing demand for advanced diagnostic solutions.

Recent Developments

• In January 2026, Illumina launched its Billion Cell Atlas, establishing the world's largest genome-wide genetic perturbation dataset. This initiative aims to accelerate artificial intelligence-driven drug discovery across the pharmaceutical ecosystem by mapping how one billion individual cells respond to genetic changes via CRISPR technology across over 200 disease-relevant cell lines. The atlas is designed to enable breakthroughs in disease diagnosis, drug discovery, and precision medicine, offering a comprehensive understanding of human disease biology and directly impacting the advancement of CRISPR-based diagnostic capabilities.
• In December 2025, Sherlock Biosciences, a company leveraging CRISPR-based technologies for molecular diagnostics, anticipated submitting its Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) self-test to the U.S. Food and Drug Administration (FDA) for review. This development followed the company's acquisition by OraSure Technologies in December 2024, integrating Sherlock's advanced molecular diagnostics platform designed for rapid, accurate results in a disposable, over-the-counter format. Subject to regulatory approvals, the CT/NG test was expected to begin contributing to OraSure's revenue growth starting in 2026, expanding the portfolio of rapid diagnostics for sexually transmitted infections.
• In September 2025, VedaBio expanded its CRISPR molecular detection platform through a collaboration that leveraged technology from Mammoth Biosciences. This partnership aimed to enhance VedaBio's diagnostic capabilities by integrating Mammoth Biosciences' expertise in CRISPR systems, which are instrumental in identifying disease-causing biomarkers. The collaboration underscores a strategic move within the global CRISPR-based diagnostics market, focusing on advancing molecular detection methods for various applications. It further strengthens the development of next-generation diagnostic tools capable of operating across diverse settings.
• In February 2025, Illumina introduced a high-throughput method for single-cell CRISPR research, enabling scientists to interrogate the entire transcriptome of individual cells following gene perturbation by CRISPR-Cas9. This Perturb-seq solution was expected to launch commercially by the end of 2025, bringing new capabilities to Illumina's multiomics portfolio. This breakthrough research provides an unprecedented scale for single-cell analysis, significantly aiding in the discovery of disease mechanisms and the identification of potential biomarkers critical for detection and diagnostic strategies within the CRISPR-based diagnostics market.

Key Market Players

• Thermo Fisher Scientific Inc.
• Integrated DNA Technologies, Inc.
• Molbio Diagnostics
• Horizon Discovery
• Synthego Corporation
• Mammoth Biosciences
• Sherlock Biosciences
• Caribou Biosciences
• CrisprBits
• ToolGen Inc.

By Product	By Technology	By Application	By End User	By Region
Enzymes Kits and Reagents Software Libraries	Cas9 Cas12 Others	Infectious Disease Diagnostics Genetic Disorder Diagnostics Cancer Diagnostics Others	Hospitals and Clinics Diagnostic Laboratories Pharmaceutical and Biotechnology Companies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global CRISPR-Based Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• CRISPR-Based Diagnostics Market, By Product:

• Enzymes
• Kits and Reagents
• Software
• Libraries

• CRISPR-Based Diagnostics Market, By Technology:

• Cas9
• Cas12
• Others

• CRISPR-Based Diagnostics Market, By Application:

• Infectious Disease Diagnostics
• Genetic Disorder Diagnostics
• Cancer Diagnostics
• Others

• CRISPR-Based Diagnostics Market, By End User:

• Hospitals and Clinics Diagnostic
• Laboratories
• Pharmaceutical and Biotechnology Companies
• Others

• CRISPR-Based Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE